DE2139183A1 - Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid - Google Patents
Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acidInfo
- Publication number
- DE2139183A1 DE2139183A1 DE19712139183 DE2139183A DE2139183A1 DE 2139183 A1 DE2139183 A1 DE 2139183A1 DE 19712139183 DE19712139183 DE 19712139183 DE 2139183 A DE2139183 A DE 2139183A DE 2139183 A1 DE2139183 A1 DE 2139183A1
- Authority
- DE
- Germany
- Prior art keywords
- monophosphoric acid
- contg
- compsns
- addns
- pharm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Beschreibung Kosmetische und pharmazeutische Zuboreitungen Die kosmetischen (und pharmazeutischen) Präparate, die u.s. Hormone (Östrogene, Gestagene, Androgene usw.), anabolische Steroide und/oder Vitamine und Vitaminoide authalten, haben oft eine unsichere Wirkung. Es wurde nun gefunden, dass die wirkung der genannten Stoffs signifikant protahiert wird, kann den kosmetischen und pharmazeutischen Präproten "cyclische Adenosinmonophosphorsäure"(Adenosin-3,54 monophosphorsäure cyclisch ; c-AMP) oder deren Derivate bzw .verwandte Verbindungen, beispielsweise cycl. Dibutyryl-3,5'-adanosinphosphorsäure, Dibutyryl-gunanesin-3,5-monophosphorsäure cyclisch oder die Monobutyrylverbindungen in .-orm der Säute bzw.deren Salze zugesetzt werden.Die Butyrylgruppen erhöhen die Ed@@löslichkeit und sie können durch Valerylgruppen oder andere Gruppen ersetzt werden. Description Cosmetic and pharmaceutical accessories The cosmetic (and pharmaceutical) preparations containing u.s. Hormones (estrogens, progestins, androgens etc.), anabolic steroids and / or vitamins and vitaminoids are often used an uncertain effect. It has now been found that the effect of the substance mentioned The cosmetic and pharmaceutical preproteins can be significantly protahed "cyclic adenosine monophosphoric acid" (adenosine-3.54 monophosphoric acid cyclic; c-AMP) or their derivatives or related compounds, for example cycl. Dibutyryl-3,5'-adanosine phosphoric acid, Dibutyryl-gunanesin-3,5-monophosphoric acid cyclic or the monobutyryl compounds in. -orm of the acids or their salts. The butyryl groups increase the Ed @@ solubility and they can be replaced by valeryl groups or other groups will.
Da die c-2MP kaum permeabel ist und ebnso wenig die Alkalisalze ist so bsmerkenswert, dass die Alkylolaminsalse nennenswert parpeabel sind, wes einen Fort ohritt in der Anwendung bedeutet.Since the c-2MP is hardly permeable and the alkali salts are just as little so remarkable that the alkylolamine salts are appreciably parpeable, which is one of them Continuing in the application means.
Dis Zusammensetzung der Kosmetika ist die übliche, sie können glüssig bi cremeförmig sein.The composition of cosmetics is the usual, they can be smooth bi be creamy.
is wislfältigen physiologischen Wirkungen der c-AMP sind bekennt und die Adenosintriphosphate bzw.die Salze wurden bereits für Kosmetika empfohlen;sie sind nicht permeabel und haben nicht die breite Wirkung der c-AMP oder deren Derivate. The wise physiological effects of c-AMP are known and the adenosine triphosphates or salts have already been recommended for cosmetics; they are not permeable and do not have the broad effect of c-AMP or its derivatives.
als sogenannter sekundärer Massenger(@second messenger") leitet en zellspesifische hormonale Informationen, wolche vermutlich @@ defür geignete Rezsptoren der Zallmembran angrofien im Zellinnern weiter. Le lässt sich beispielsweise die Wirkung des adreaccorticotropen @ormens (ACTI) auf die nebennierenrinde (z.B.Cortiostaroid-Ausschüttung) durch lokale Applikation von c-AMP ersetzen.as a so-called secondary masseger (@second messenger ") leads en Cell-specific hormonal information, presumably want @@ for suitable receptors the cell membrane continued to grow inside the cell. Le can, for example, the Effect of the adreaccorticotropic norm (ACTI) on the adrenal cortex (e.g. cortiostaroid secretion) Replace with local application of c-AMP.
de vielen Untersuchungen der latzten dahre haben gezeigt, dass @@
c-AMP eine wegentliche Rolle bei der Enzymaktiviorung und Zellwundpermcabilitätsänderungen
im Zellstoffwechsel spielt. Frst die Anspr@@it von c-AMP ermöglicht die lebensnotwendigen
Transpiption
Versuche an den enthsarten Flanken von Mcerschweinchen mit einer O/W-Emulsion mit c-AMP(Colaminsalz) und c-Dibutyryl-AMP ergab Akanthose der Haut und dautliche Proliforation. Die Befunde wur den bei Zusatz von anabolischen Steroiden noch verbessert und diese konnten in den Mengen geminlert werden. Darin ist ein beachtlicher technischer Vorteil zu erblicken,denn viele anabolischen Steroide sind physiologisch nicht so harmlos als in der Literatur dargestellt (Nabensffekte).Zu erwähnen sind u.a.Ethisteron, api-Androsterdn.Experiments on the dehumidified flanks of McPigs with an O / W emulsion with c-AMP (colamine salt) and c-dibutyryl-AMP resulted in acanthosis of the skin and similar Proliferation. The findings were improved with the addition of anabolic steroids and these could be reduced in quantity. There is a considerable technical in it Advantage to see, as many anabolic steroids are physiologically not like that harmless than presented in the literature (hub effects), such as ethisterone, api-Androsterdn.
in erheblicher Vorteil besteht auch darin,dass die c-AMP und D-rivate streng lokale Wirkungen am Zielorgan, also bier der Haut entfalten. Sie vermag nicht event.nachteilig in den Gesamtatoffwechsel einzugreifen, wie das bei Östrogenen zu befürchten ist.There is also a considerable advantage in the fact that the c-AMP and D-derivatives Strictly develop local effects on the target organ, i.e. on the skin. She cannot possibly interfering adversely with the overall metabolism, as is the case with estrogens is to be feared.
Durch die c-AMT bzw. Derivaten ist en möglich den Energiestoffwechsel der Zelle äusserlich massgeblich zu beeinflussen.The c-AMT or derivatives enable the energy metabolism to influence the cell externally significantly.
Disse Eigenschaften machen die c-AMP und Derivate au cinem wichtigen Bestandteil zahlreicher kosmetischer und/oder pharmazeutischen Zubereitungen.These properties make the c-AMP and derivatives also important Component of numerous cosmetic and / or pharmaceutical preparations.
Beispiele: Hasrwasser: 55,0 Äthanol oder Igopropanol 44,0 Wasser, destilliert 0,2 Panthenol 0,2 Salicylsäure 0,05 Laurylpyridiniumchlorid 0,1 Camphersäure 0,2 Dipropylenglykol 01 Polyvinylpyrrolidon rein 0r25 Riechstoffe 5 -50 mg Dibutyrul-adenosin-3,5-monophesphat-Colaminsalz cycl.Examples: Hasr water: 55.0 ethanol or Igopropanol 44.0 water, distilled 0.2 panthenol 0.2 salicylic acid 0.05 laurylpyridinium chloride 0.1 camphoric acid 0.2 dipropylene glycol 01 polyvinylpyrrolidone pure 0r25 fragrances 5 - 50 mg dibutyrul-adenosine-3,5-monophesphate-colamine salt cycl.
+ 10 -100 mg c-AMP -alkylolaminsalz je 1000 ml Bautoremo : 10,0 Paraffinöl, niedrigviskos 5,0 Erdnussöl, konserviert 8,0 Miglyol 812 (ein Triglycerid) 7,0 Ischexadecylisostcarat 2,0 Lanolinöl, hell 9,0 @achsemulgator mit Tensiden 3,0 Glycerin IAB 7 0,2 Chloracetamid 0,5 magnesiumsulfat kristallisiert 53,0 @@sser, desstillier56t 2,0 Citratpuffer (pH-5,5-6,5); 1,10-3 molar 5 - 50 mg c-Dibutyl-AMP-aminsalz + (oder) 10-100 mg c- AMP je 1 kg Emulsion Herstellung : Die Emulsion wird bei etda 75-80° be Berücksichtigte Literatur: I. Karlson: irkungsmechanismen der Hormone. 18.Coll.d.Ges. + 10 -100 mg c-AMP -alkylolamine salt per 1000 ml Bautoremo: 10.0 paraffin oil, Low viscosity 5.0 Peanut oil, preserved 8.0 Miglyol 812 (a triglyceride) 7.0 Ischexadecyl isostcarate 2.0 Lanolin oil, light 9.0 Axial emulsifier with surfactants 3.0 Glycerin IAB 7 0.2 Chloracetamide 0.5 magnesium sulfate crystallizes 53.0 @@ sser, desstillier56t 2.0 citrate buffer (pH 5.5-6.5); 1.10-3 molar 5 - 50 mg c-dibutyl-AMP-amine salt + (or) 10-100 mg c- AMP per 1 kg of emulsion Production: The emulsion is at around 75-80 ° Considered Literature: I. Karlson: mechanisms of action of the hormones. 18.Coll.d.Ges.
f. Physiol. Chemie. Mosbach 1967. Springer-Verlag, Berlin 1967 W. Blech: Die biochem. Wirkungsweise der Hormone. Naturwiss. f. Physiol. Chemistry. Mosbach 1967. Springer-Verlag, Berlin 1967 W. Blech: The biochem. How the hormones work. Natural science
Rdsch. 11, 459(1968) E.J.V.J. Christ: Fette-Seifen-Anstrichmittel 10, 849 ( 14. Tausk: Pharmakologie der Hormone.Georg Thieme Verlag (1970) J. Pastan u. R.L. Perlmann: Cyclic AMP in Metabolism. Rdsch. 11, 459 (1968) E.J.V.J. Christ: Fette-Soap-Paint 10, 849 (14. Tausk: Pharmakologie der Hormone. Georg Thieme Verlag (1970) J. Pastan u. R.L. Perlmann: Cyclic AMP in Metabolism.
Nature New Biology Vol. 229 Jan.6 ; p.5 (1971) R.C. Haymes, S.B.Koritz u.F.O.Peron: J.Biol.Chem.234,1421 (1959) @.@. Sutherland, R.W. Butcher, G.A. Robison, I.G.Hardman: The role of adenosin-3,5'-monophosphat in hormone action. Aus: (1).S.1 Y. Oshima, T.Horiuchi, Y.Iida u.T. Kameyama. Mol.Gen.Genetics 106, 307 (1970) E. Böhme, K.Munske u.G.Schultz. Nannyn-Schmiedebergs Arch. Nature New Biology Vol. 229 Jan.6; p.5 (1971) R.C. Haymes, S.B. Koritz u.F.O. Peron: J.Biol.Chem. 234, 1421 (1959) @. @. Sutherland, R.W. Butcher, G.A. Robison, I.G. Hardman: The role of adenosine-3,5'-monophosphate in hormone action. From: (1) .S.1 Y. Oshima, T. Horiuchi, Y.Iida & T. Kameyama. Mol. Gen. Genetics 106, 307 (1970) E. Böhme, K. Munske and G. Schulz. Nannyn-Schmiedeberg's Arch.
Pbarmakol. 264, 220 (1969) J.F. Kuo, J.Sanes u.P.Greengard. Federation Proceedings 29, 1990(1970) Pbarmakol. 264, 220 (1969) J.F. Kuo, J. Sanes, and P. Greengard. Federation Proceedings 29, 1990 (1970)
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19712139183 DE2139183A1 (en) | 1971-08-05 | 1971-08-05 | Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19712139183 DE2139183A1 (en) | 1971-08-05 | 1971-08-05 | Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid |
Publications (1)
Publication Number | Publication Date |
---|---|
DE2139183A1 true DE2139183A1 (en) | 1973-02-15 |
Family
ID=5815851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19712139183 Pending DE2139183A1 (en) | 1971-08-05 | 1971-08-05 | Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE2139183A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0256472A2 (en) * | 1986-08-11 | 1988-02-24 | Lion Corporation | Cosmetic agent for application to skin |
EP0260697A2 (en) | 1986-09-18 | 1988-03-23 | Lion Corporation | Composition for application to hair |
JPS63183518A (en) * | 1986-09-18 | 1988-07-28 | Lion Corp | Composition for hair |
EP0332847A2 (en) * | 1988-03-16 | 1989-09-20 | Lion Corporation | Composition for preventing graying of the hair and restoring grayed hair to its natural color |
EP0435180A1 (en) * | 1989-12-27 | 1991-07-03 | Lion Corporation | Composition for treating hair |
US5185150A (en) * | 1990-08-24 | 1993-02-09 | Wisconsin Alumni Research Fdn. | Cosmetic compositions containing 19-nor-vitamin D compounds |
US5376643A (en) * | 1986-09-18 | 1994-12-27 | Lion Corporation | Composition for application to hair |
-
1971
- 1971-08-05 DE DE19712139183 patent/DE2139183A1/en active Pending
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0256472A2 (en) * | 1986-08-11 | 1988-02-24 | Lion Corporation | Cosmetic agent for application to skin |
EP0256472A3 (en) * | 1986-08-11 | 1988-09-07 | Lion Corporation | Cosmetic agent for application to skin |
EP0260697A2 (en) | 1986-09-18 | 1988-03-23 | Lion Corporation | Composition for application to hair |
JPS63183518A (en) * | 1986-09-18 | 1988-07-28 | Lion Corp | Composition for hair |
EP0260697A3 (en) * | 1986-09-18 | 1988-08-31 | Lion Corporation | Composition for application to hair |
US5376643A (en) * | 1986-09-18 | 1994-12-27 | Lion Corporation | Composition for application to hair |
EP0332847A2 (en) * | 1988-03-16 | 1989-09-20 | Lion Corporation | Composition for preventing graying of the hair and restoring grayed hair to its natural color |
EP0332847A3 (en) * | 1988-03-16 | 1990-04-11 | Lion Corporation | Composition for preventing graying of the hair and restoring grayed hair to its natural color |
EP0435180A1 (en) * | 1989-12-27 | 1991-07-03 | Lion Corporation | Composition for treating hair |
US5185150A (en) * | 1990-08-24 | 1993-02-09 | Wisconsin Alumni Research Fdn. | Cosmetic compositions containing 19-nor-vitamin D compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0291863B1 (en) | Mixed crystals of insulin and insulin derivatives, their process of manufacture and pharmaceutical agents containing them | |
KR930012013A (en) | Pharmaceutical ingredients used topically to treat psoriasis and irritable dermatitis | |
DE2139183A1 (en) | Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid | |
DE2124752A1 (en) | Process for the production of a diagnostic preparation based on macroaggregates of serum protein labeled with 99mTc | |
DE2610020A1 (en) | PHARMACEUTICAL COMPOSITION | |
DE2164052A1 (en) | COSMETIC AGENTS WITH NUCLEOSIDE DERIVATIVES | |
DE2920020C2 (en) | ||
GB1356635A (en) | Deodorising and anti-seborrhoeic compositions | |
DE1617871A1 (en) | Process for the production of a stable aqueous solution | |
DE2551480C3 (en) | Technetium-99m-labeled kidney diagnostic and process for its preparation | |
DE1142428B (en) | Skin and hair care products | |
DE1642612A1 (en) | The use of erythrocytes to obtain or isolate a plasminogen activator | |
CH676424A5 (en) | ||
EP0003041B1 (en) | Technetium-99m marked diagnostic composition for the representation of the reticuloendothelial system (res) and process for its preparation | |
DE940060C (en) | Process for the production of aqueous solutions of drugs that are poorly soluble in water | |
Berrens et al. | Preparation and properties of purified house dust allergen | |
DE2725765A1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING THIAZOLE DERIVATIVES | |
DE3216026A1 (en) | TECHNETIUM (99M) MARKED ISONICOTINIC HYDRAZIDE, METHOD FOR THE PRODUCTION THEREOF AND A PHARMACEUTICAL AGENT CONTAINING THIS COMPOUND | |
DE1692463A1 (en) | Stimulant for the growth and development of animals and poultry and processes for the production thereof | |
EP0108248B2 (en) | Aqueous nitroglycerine solution free of solubilizers | |
DE930171C (en) | Process for the production of aqueous solutions of steroid hormones | |
DE967872C (en) | Process for the production of aqueous solutions of drugs that are poorly soluble in water | |
DE925541C (en) | Process for the production of aqueous solutions of drugs that are poorly soluble in water | |
DE801839C (en) | Process for preparing an organic salt of ª-methylmercapto-ª-aminobutyric acid | |
AT345482B (en) | PROCESS FOR THE PRODUCTION OF NEW INSULIN DERIVATIVES |